BioNTech announces launch of MammaTyper test to improve breast cancer treatment

[News]

BioNTech AG, a fully integrated biotechnology company developing truly personalized cancer immunotherapies and its subsidiary BioNTech Diagnostics GmbH, today announced the launch of MammaTyper, a CE-IVD marked molecular diagnostic test to stratify breast cancer patients by molecular subtyping of routine tumor tissue, for universal use in pathology laboratories.

More... (http://www.news-medical.net/news/20150611/BioNTech-announces-launch-of-MammaTyper-test-to-improve-breast-cancer-treatment.aspx)